Literature DB >> 27135718

Genomics of Alzheimer Disease: A Review.

Roger N Rosenberg1, Doris Lambracht-Washington2, Gang Yu3, Weiming Xia4.   

Abstract

IMPORTANCE: To provide a comprehensive review of knowledge of the genomics of Alzheimer disease (AD) and DNA amyloid β 42 (Aβ42) vaccination as a potential therapy. OBSERVATIONS: Genotype-phenotype correlations of AD are presented to provide a comprehensive appreciation of the spectrum of disease causation. Alzheimer disease is caused in part by the overproduction and lack of clearance of Aβ protein. Oligomer Aβ, the most toxic species of Aβ, causes direct injury to neurons, accompanied by enhanced neuroinflammation, astrocytosis and gliosis, and eventually neuronal loss. The strongest genetic evidence supporting this hypothesis derives from mutations in the amyloid precursor protein (APP) gene. A detrimental APP mutation at the β-secretase cleavage site linked to early-onset AD found in a Swedish pedigree enhances Aβ production, in contrast to a beneficial mutation 2 residues away in APP that reduces Aβ production and protects against the onset of sporadic AD. A number of common variants associated with late-onset AD have been identified including apolipoprotein E, BIN1, ABC7, PICALM, MS4A4E/MS4A6A, CD2Ap, CD33, EPHA1, CLU, CR1, and SORL1. One or 2 copies of the apolipoprotein E ε4 allele are a major risk factor for late-onset AD. With DNA Aβ42 vaccination, a Th2-type noninflammatory immune response was achieved with a downregulation of Aβ42-specific effector (Th1, Th17, and Th2) cell responses at later immunization times. DNA Aβ42 vaccination upregulated T regulator cells (CD4+, CD25+, and FoxP3+) and its cytokine interleukin 10, resulting in downregulation of T effectors. CONCLUSIONS AND RELEVANCE: Mutations in APP and PS-1 and PS-2 genes that are associated with early-onset, autosomal, dominantly inherited AD, in addition to the at-risk gene polymorphisms responsible for late-onset AD, all indicate a direct and early role of Aβ in the pathogenesis of AD. A translational result of genomic research has been Aβ-reducing therapies including DNA Aβ42 vaccination as a promising approach to delay or prevent this disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27135718      PMCID: PMC6759853          DOI: 10.1001/jamaneurol.2016.0301

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  37 in total

Review 1.  The Translational Significance of the Neurovascular Unit.

Authors:  Heather L McConnell; Cymon N Kersch; Randall L Woltjer; Edward A Neuwelt
Journal:  J Biol Chem       Date:  2016-12-05       Impact factor: 5.157

Review 2.  Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps.

Authors:  Michael Fenech
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

3.  Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer's Disease.

Authors:  Marat A Mukhamedyarov; Albert A Rizvanov; Eduard Z Yakupov; Andrey L Zefirov; Andrey P Kiyasov; Helton J Reis; Antônio L Teixeira; Luciene B Vieira; Luciana M Lima; Ilnur I Salafutdinov; Elena O Petukhova; Svetlana F Khaiboullina; Karen A Schlauch; Vincent C Lombardi; András Palotás
Journal:  J Alzheimers Dis       Date:  2016-10-18       Impact factor: 4.472

4.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

6.  A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients.

Authors:  Allison L Cirino; Neal K Lakdawala; Barbara McDonough; Lauren Conner; Dale Adler; Mark Weinfeld; Patrick O'Gara; Heidi L Rehm; Kalotina Machini; Matthew Lebo; Carrie Blout; Robert C Green; Calum A MacRae; Christine E Seidman; Carolyn Y Ho
Journal:  Circ Cardiovasc Genet       Date:  2017-10

Review 7.  Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases.

Authors:  Scott T Brady; Gerardo A Morfini
Journal:  Neurobiol Dis       Date:  2017-04-11       Impact factor: 5.996

8.  rs3851179 Polymorphism at 5' to the PICALM Gene is Associated with Alzheimer and Parkinson Diseases in Brazilian Population.

Authors:  Cíntia Barros Santos-Rebouças; Andressa Pereira Gonçalves; Jussara Mendonça Dos Santos; Bianca Barbosa Abdala; Luciana Branco Motta; Jerson Laks; Margarete Borges de Borges; Ana Lúcia Zuma de Rosso; João Santos Pereira; Denise Hack Nicaretta; Márcia Mattos Gonçalves Pimentel
Journal:  Neuromolecular Med       Date:  2017-05-31       Impact factor: 3.843

9.  Prostaglandin A1 Decreases the Phosphorylation of Tau by Activating Protein Phosphatase 2A via a Michael Addition Mechanism at Cysteine 377.

Authors:  Guo-Biao Xu; Pei-Pei Guan; Pu Wang
Journal:  Mol Neurobiol       Date:  2020-10-23       Impact factor: 5.590

Review 10.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.